| Filed On | Filing |
|---|---|
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren’s disease will be shared in December |
| 10 Nov 2026 | SCHEDULE 13G |
| 09 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 |
| 06 Nov 2026 |
Form 4: Michaelson Jennifer, Chief Scientific Officer
Received 3,805 shares by exercise or conversion ($16.4K) · Sold 4,000 shares ($49.4K) |
| 05 Nov 2026 | 144 |
| 04 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting |
| 02 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program |
| 24 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer |
| 10 Sep 2026 |
Form 4: Michaelson Jennifer, Chief Scientific Officer
Received 4,000 shares by exercise or conversion ($17.2K) · Sold 8,000 shares ($173K) |
| 08 Sep 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 |
Form 4: Michaelson Jennifer, Chief Scientific Officer
Received 30,000 shares by exercise or conversion ($129K) · Sold 30,000 shares ($608K) |
| 14 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | 144 |
| 13 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 |
Loading...